Effect of supplementation in treatment of patients with diabetic nephropathy

Clinical trial of the effect of coenzyme Q10 supplementation compared with the placebo on gene expression involved in insulin, lipid and inflammation signaling pathway in patients with diabetic nephropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201611155623N93

Enrollment

Registered

2016-11-22

Start date

2015-11-06

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy. Glomerular disorders in diabetes mellitus (E10-E14 with common fourth character .2+)

Interventions

Intervention 1: Intervention group: 100 mg coenzyme Q10 (Nature, New York, USA), once a day, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), once a day, for

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with diabetic nephropathy Aged 40 to 80 years

Exclusion criteria

Exclusion criteria: Consumption of any nutritional supplements within 3 months History of active infection within 3 months History of hospital admission within 3 months Malignancy and/or liver cirrhosis Subjects with uncontrolled diabetes Pregnant women

Design outcomes

Primary

Measure	Time frame
Expressed levels of PPAR-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of GLUT-1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Expressed levels of Lp(a) gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of LL-1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of LL-8 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of ox-LDL gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-B gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

Expressed levels of Lp(a) gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of LL-1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of LL-8 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of ox-LDL gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-B gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026